美康生物(300439.SZ)半年度淨利潤升1.49%至1.3億元
格隆匯8月16日丨美康生物(300439.SZ)發佈2019年半年度報告,實現營業收入15.26億元,同比增長4.68%;歸屬於上市公司股東的淨利潤1.30億元,同比增長1.49%;歸屬於上市公司股東的扣除非經常性損益後的淨利潤1.18億元,同比增長14.55%;基本每股收益0.38元。經營活動產生的現金流量淨額2.43億元,同比增長488.65%。
2019年上半年,公司管理層圍繞董事會制定的年度經營計劃和目標,積極推進並落實各項重要工作。一方面,持續加大研發投入,豐富公司產品線,打造IVD全產業鏈佈局,加大核心產品和新產品的市場推廣力度和渠道建設;另一方面,不斷提高內部管理水平,優化資源配置,完善績效考核,穩步推進和優化區域醫學檢驗共享中心連鎖化業務及醫學檢驗集約化業務,推進公司“以診斷產品為核心,診斷產品+診斷服務”一體化戰略佈局的實施,使得公司主營業務和經營業績保持持續穩定發展。
2019年上半年研發投入5306.92萬元,比上年同期增加了8.13%,有力的支持了公司的項目研發和創新發展;二是完善研發質量管理體系及績效考核體系,推進跨部門項目管理,確保研發工作的有效、有序的進行;三是在夯實生化系列產品的基礎上,加快對化學發光、分子診斷、質譜、VAP(血脂分型及血脂顆粒檢測)血脂等領域及關鍵原料的研發進度;四是有序推進產品註冊申報,報告期內,公司新取得16項境內產品註冊證,10項境外產品認證。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.